Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

被引：0

作者：

Price, Timothy ^{[1
,2
]}

Kopetz, Scott ^{[3
]}

Grothey, Axel ^{[4
]}

Van Cutsem, Eric ^{[5
]}

Yaeger, Rona ^{[6
]}

Wasan, Harpreet Singh ^{[7
]}

Yoshino, Takayuki ^{[8
]}

Desai, Jayesh ^{[9
]}

Ciardiello, Fortunato ^{[10
]}

Loupakis, Fotios ^{[11
]}

Hong, Yong S. ^{[12
]}

Steeghs, Neeltje ^{[13
]}

Guren, Tormod K. ^{[14
]}

Arkenau, Hendrik-Tobias ^{[15
]}

Garcia-Alfonso, Pilar ^{[16
]}

Chantrill, Lorraine ^{[17
,18
]}

Tebbutt, Niall ^{[19
]}

Strickland, Andrew ^{[20
,21
]}

Karapetis, Chris ^{[22
,23
]}

Murphy, Felicity ^{[24
]}

Gollerkeri, Ashwin ^{[25
,26
]}

Maharry, Kati ^{[25
,26
]}

Christy-Bittel, Janna ^{[25
,26
]}

Tabernero, Josep ^{[27
]}

机构：

[1] Queen Elizabeth Hosp, Med Oncol Unit, Adelaide, SA, Australia

[2] Univ Adelaide, Adelaide, SA, Australia

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] West Canc Ctr, Germantown, TN USA

[5] Katholieke Univ Leuven, Univ Hosp Gasthuisberg Leuven, Leuven, Belgium

[6] Mem Sloan Kettering Canc Ctr, New York, NY USA

[7] Imperial Coll Hlth Care Trust, Hammersmith Hosp, London, England

[8] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[9] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[10] Univ Campania, Naples, Italy

[11] Ist Toscano Tumori, Pisa, Italy

[12] Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea

[13] Netherlands Canc Inst, Amsterdam, Netherlands

[14] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[15] Sarah Cannon Res Inst UK Ltd, London, England

[16] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[17] St Vincents Hosp, Sydney, NSW, Australia

[18] Wollongong Hosp, Illawarra Canc Care Ctr, Wollongong, NSW, Australia

[19] Austin Hlth, Med Oncol, Melbourne, Vic, Australia

[20] Monash Hlth, Melbourne, Vic, Australia

[21] Monash Univ, Melbourne, Vic, Australia

[22] Flinders Med Ctr, Adelaide, SA, Australia

[23] Flinders Univ S Australia, Adelaide, SA, Australia

[24] Mater Hosp, Brisbane, Qld, Australia

[25] Pfizer Inc, Cambridge, MA USA

[26] Pfizer Inc, Boulder, CO USA

[27] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 16卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

242

引用

页码：128 / 128

页数：1

共 50 条

[31] Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
Boccaccino, A.
Borelli, B.
Intini, R.
Antista, M.
Bensi, M.
Rossini, D.
Passardi, A.
Tamberi, S.
Giampieri, R.
Antonuzzo, L.
Noto, L.
Roviello, G.
Zichi, C.
Salati, M.
Puccini, A.
Noto, C.
Parisi, A.
Rihawi, K.
Persano, M.
Crespi, V
Libertini, M.
Giordano, M.
Moretto, R.
Lonardi, S.
Cremolini, C.
[J]. ESMO OPEN, 2022, 7 (03)
[32] BEACON CRC (binimetinib [BIM], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)ICTX with
Huijberts, Sanne
Schellens, Jan H. M.
Fakih, Marwan
Peeters, Marc
Kopetz, Scott
Grothey, Axel
Van Cutsem, Eric
Wasan, Harpreet Singh
Desai, Jayesh
Ciardiello, Fortunato
Yoshino, Takayuki
Maharry, Kati
Gollerkeri, Ashwin
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[33] Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study
Kato, T.
Kotani, D.
Takashima, A.
Satoh, T.
Masuishi, T.
Komatsu, Y.
Shiozawa, M.
Esaki, T.
Izawa, N.
Takeuchi, S.
Bando, H.
Iwasa, S.
Hasegawa, H.
Yamaguchi, T.
Taniguchi, H.
Yamada, S.
Yoshino, T.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S21 - S22
[34] BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib plus MEK inhibitor binimetinib plus anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer
Van Cutsem, E.
Cuyle, P.
Huijberts, S.
Schellens, J.
Elez, E.
Yaeger, R.
Fakih, M.
Montagut, C.
Peeters, M.
Desai, J.
Yoshino, T.
Ciardiello, F.
Wasan, H.
Maharry, K.
Christy-Bittel, J.
Gollerkeri, A.
Kopetz, S.
Grothey, A.
Tabernero, J.
[J]. ANNALS OF ONCOLOGY, 2018, 29
[35] Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naive metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study
Parikh, Aparna Raj
Chiorean, E. Gabriela
Atreya, Chloe Evelyn
Zheng, Lei
Kopetz, Scott
Spira, Alexander I.
Spigel, David R.
Cui, Yue
Osgood, Ryan
Tran, Rebecca
Morris, Shannon R.
Ulahannan, Susanna Varkey
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab plus /-binimetinib (E-C plus /-B)
Montana, F. J. Ros
Navarro, V.
Comas, R.
Rodriguez, A. Garcia
Gomez, D.
Gonzalez, N. Saoudi
Vicente, P.
Cuadra, J. L.
Paez, D.
Alonso, V.
Martinez, A. Hernandez
Valbuena, D. E. Lopez
Argota, I. Baraibar
Ballabrera, F. Salva
Tabernero, J.
Fernandez, M. E. Elez
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S707 - S707
[37] BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)
Huijberts, S.
Schellens, J. H. M.
Elez, E.
Cuyle, P-J.
Van Cutsem, E.
Yaeger, R.
Fakih, M.
Montagut, C.
Peeters, M.
Desai, J.
Yoshino, T.
Ciardiello, F.
Wasan, H.
Grothey, A.
Maharry, K.
Gollerkeri, A.
Kopetz, S.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[38] ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BIM), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC)
Grothey, A.
Yaeger, R.
Paez, D.
Tabernero, J.
Taieb, J.
Yoshino, T.
Groc, M.
Vedovato, J.
Chetaille, E.
Van Cutsem, E.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
[39] Pierre Fabre and its Partner Array BioPharma announce the Interim Results of the BEACON CRC Study with Encorafenib plus Binimetinib plus Cetuximab for the Treatment of BRAFV600E-mutant metastatic Colon Cancer (mCRC)
不详
[J]. VISCERAL MEDICINE, 2019, 35 (05) : 330 - 330
[40] Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
Taieb, Julien
Lonardi, Sara
Desai, Jayesh
Folprecht, Gunnar
Gallois, Claire
Marques, Eduardo Polo
Khan, Sadya
Castagne, Claire
Wasan, Harpreet
[J]. CLINICAL COLORECTAL CANCER, 2023, 22 (01) : 59 - 66

← 1 2 3 4 5 →